EcoDrugPlus

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBGRG00000009828
Gene Symbol: PIM1
1 Cross references
248 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBGRG00000018477
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBGRG00000002237
Gene Symbol: PIM3
1 Cross references
196 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSBGRG00000002783
Gene Symbol: RORC
1 Cross references
383 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSBGRG00000006479
Gene Symbol: ROS1
1 Cross references
125 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBGRG00000022891
Gene Symbol: RAF1
1 Cross references
224 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSBGRG00000017206
Gene Symbol: ROCK1
1 Cross references
211 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSBGRG00000024309
Gene Symbol: ROCK2
1 Cross references
298 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSBGRG00000005672
Gene Symbol: SRC
1 Cross references
261 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSBGRG00000000666
Gene Symbol: TEK
1 Cross references
166 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSBGRG00000003901
Gene Symbol: TTK
1 Cross references
205 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSBGRG00000003727
Gene Symbol: UGCG
1 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).